Zhejiang Ausun Pharmaceutical Co Ltd [Photo/zjtz.gov.cn]

Zhejiang Ausun Pharmaceutical Co Ltd, a technology-driven high-tech enterprise, was founded in Linhai of Taizhou, Zhejiang province in April 2010. It was successfully listed on the Shanghai Stock Exchange on May 9, 2017, with a stock code of 603229.

The company is mainly engaged in the research and development (R&D), production and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, as well as provision of customized production and R&D services to customers.

[Photo/ausunpharm.com]

The company's main products are specialty APIs and pharmaceutical intermediates with many characteristics, such as multi-chiral structure, high difficulty of research and development, high technical barriers and unique production processes. The products are divided into six categories - liver disease, respiratory system disease, cardiovascular and cerebrovascular disease, high-end fluoride products, prostaglandins and antibacterials, among them, the hepatitis treatment drug Entecavir has been approved by the official GMP certification of Cyprus and the US Food and Drug Administration. In addition, several products of the company have obtained European Union export certification documents, and many others are in process to obtain serial numbers in multiple countries.